Generic Drug Reverse Engineering: The Complete Analyst’s Guide to Deformulation, IP Strategy, and ANDA Approval
1. Why Deformulation Is a Patent Strategy Weapon Reverse engineering a branded drug is not simply a chemistry exercise. It […]
Who Owns the AI-Designed Drug? The Patent, Valuation, and IP Strategy Guide Pharma Needs Now
A technical reference for pharma IP counsel, portfolio managers, R&D strategy leads, business development teams, and institutional investors with exposure
Canada’s PMNOC Patent Linkage System: The Complete IP Strategy Guide for Pharma Teams
What Canada’s Patent Linkage System Actually Does Canada ties the regulatory approval of generic and biosimilar drugs directly to the
Canada’s PMNOC Patent Linkage System: The Complete IP Strategy Guide for Pharma Teams Read Post »
The Dragon Awakes: Charting the Unstoppable Growth of Chinese Pharmaceuticals in the Global Market
The global pharmaceutical landscape in 2026 is no longer defined by the linear “West-innovates, East-manufactures” paradigm that dominated the early
Pharmacy Benefit Managers: The Complete Analyst’s Guide From Claims Adjudicators to Vertically Integrated Middlemen
A deep-dive for pharma/biotech IP teams, R&D leads, and institutional investors on PBM market power, formulary mechanics, IP asset valuation,
Pharma Litigation Data: The Definitive Guide to Predicting Generic Drug Launches
Why Litigation Data Outperforms Every Other LOE Signal Patent expiration dates are public. Orange Book listings are public. FDA tentative
Pharma Litigation Data: The Definitive Guide to Predicting Generic Drug Launches Read Post »
Track Any Drug Pipeline Through Patent Filings: The Pharma Analyst’s Intelligence Playbook
Track Any Drug Pipeline Through Patent Filings: The Pharma Analyst’s Intelligence Playbook Why Patent Filings Beat Every Other Intelligence Source
How to build a $20 billion monopoly: the data behind the ANDA gold rush
The pharmaceutical market in the United States functions as a regulated trade-off between the necessity of innovation and the demand
How to build a $20 billion monopoly: the data behind the ANDA gold rush Read Post »
CDMO Patent Intelligence: The Playbook for Winning Pharma Clients Before They Go to RFP
Why Patent Data Is the Most Underused BD Tool in CDMO Sales Most CDMOs sell on the same four claims:
CDMO Patent Intelligence: The Playbook for Winning Pharma Clients Before They Go to RFP Read Post »
